Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Tuesday, Aug. 4, 2026 astatine 11:00 a.m. ET

CALL PARTICIPANTS

• Chairman and Chief Executive Officer - Albert Bourla

• Chief Financial Officer - David Denton

• Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan

• Chief Scientific Officer - Chris Boshoff

• Chief Investor Relations Officer and Senior Vice President - Francesca DeMartino

Full Conference Call Transcript

Operator: Good day, everyone, and invited to Pfizer's Second Quarter 2026 Earnings Conference Call. Today's telephone is being recorded. At this time, I would similar to crook the telephone implicit to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please spell ahead, ma'am.

Francesca DeMartino: Good morning, and invited to Pfizer's net call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, convey you for joining us. This telephone is being made disposable via audio webcast astatine pfizer.com. Earlier this morning, we released our results for the 2nd 4th of 2026 via a property merchandise that is disposable connected our website astatine pfizer.com. I'm joined contiguous by Dr. Albert Bourla, our Chairman and CEO; Dave Denton, our CFO; Cecile Guegan, our incoming Interim CFO; and Chris Boshoff, our Chief Scientific Officer. After their prepared remarks, we volition unfastened the telephone for questions. Members of our enactment squad volition beryllium disposable for the Q&A session.

Before we get started, I privation to punctual you that we volition beryllium making forward-looking statements and discussing definite non-GAAP fiscal measures. I promote you to work the disclaimers successful our descent presentation, the property merchandise we issued this greeting and the disclosures successful our SEC filings, which are each disposable connected the IR website connected pfizer.com. Forward-looking statements connected the telephone are taxable to important risks and uncertainties, talk lone arsenic of the call's archetypal date, and we undertake nary work to update oregon revise immoderate of the statements. With that, I volition crook the telephone implicit to Albert.

Albert Bourla: Thank you, Francesca. Good morning, everyone, and convey you for joining our call. We had different beardown 4th of execution, driving continued strategical progress. Our revenues and adjusted diluted EPS successful the 2nd 4th erstwhile much exceeded expectations. This shows that our commercialized teams are performing with excellence and precision and that we proceed to run with fiscal discipline. We besides are gathering towards the future, advancing our R&D pipeline that provides aggregate opportunities for occurrence crossed our 4 therapeutic areas. Previously, we announced that Dave Denton would beryllium leaving Pfizer soon for different opportunity. Since then, Dave has partnered intimately with Cecile Guegan to hole for this transition.